Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Biosimilar Bridging Study Waivers: Public Health Prerogative Or Trade Secret ‘Taking’?

Executive Summary

US FDA and PhRMA may be headed for showdown over use of foreign reference product bridging studies; PhRMA says that relying on sponsor’s non-public information to waive bridging studies  would violate firm’s commercial confidential information, while FDA Commissioner Gottlieb sees ‘public health prerogative’ in considering whether data-sharing agreements with foreign regulators could help eliminate need for unnecessary studies.

Advertisement

Related Content

BsUFA III: Industry Eyes Streamlined Review Of New Indications, Phased Review Process
BsUFA III: Industry Eyes Streamlined Review Of New Indications, Phased Review Process
US FDA Gets Earful On Biologic ‘Umbrella’ Exclusivity, Patent Listings, Biosimilar Bridging Study Waivers
US FDA Gets Earful On Biologic ‘Umbrella’ Exclusivity, Patent Listings, Biosimilar Bridging Study Waivers
Biosimilars For US Market May Be Able To Rely On EU-Licensed Reference Products
Interchangeable Biosimilars: FDA Clarifies US Reference Not Mandatory For Studies
Biosimilars: Adoption Of Global Reference Comparator Would Eliminate Bridging Studies
US Comparator Requirement For Interchangeable Biosimilars Would Hurt Industry
Make Interchangeability Great Again: Biosimilar Switching Studies Need US Comparators

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

PS123843

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel